

Index

- ABA. *See* American Burn Association
- abdominal compartment syndrome (ACS)
 clinical presentation, 100–1
 complications for, 102–3
 discovery of, 98
 imaging in, 101–2
 management strategies for, 103
 pathophysiology of, 98
 risk factors for, 100–1
 surgical treatment for, 103
- abdominal perfusion pressure (APP), 102
- ABI. *See* acute brain injury
- acid base abnormalities,
 ethylene glycol toxicity, 218
 case study for, 218–19
 diagnosis of, 219–20
 management and treatment of, 222
 raised anion gap acidosis and, 220–3
 symptoms of, 220–2
- ACS. *See* abdominal compartment syndrome
- activated charcoal therapy, 170, 339
- acute brain injury (ABI),
 neuromonitoring of
 advantages and disadvantages of, 277–81
 brain tissue oxygen tension, 278–9
 case study for, 275–6
 cerebral autoregulation, 280–1
 cerebral microdialysis, 281
 cerebral oximetry, 279–80
 cerebral oxygenation, 276–8
 through clinical examination, 276
 with EEG, 281–2
 GCS score, 276–8
 jugular venous oximetry, 276–8
- multimodal applications, 282
 with TCD, 280
 use of ICP, 276
- acute immune hepatitis (AIH), 191–2
 treatment of, 191–2
- acute interstitial pneumonitis (AIP), 125
- acute ischaemic stroke (AIS)
 airway and respiratory management, 61
 antiplatelet therapy, 63
 blood pressure management and, 59–62
 care pathways, 59
 case study, 57–9
 depressive craniectomy and, 62
 dysphagia after, 61
 FAST scale, 58–9
 glucose management and, 59–62
 hyperglycaemia and, 22, 62
 hypertension and, 61–2
 hypotension and, 62
 hypoxaemia after, 61
 ICP and, 60
 ICU admission indications, 59–60
 incidence rates for, 57
 infection risks with, 63
 oxygen management and, 59–61
 seizures as result of, 63
 temperature management and, 59–61
 thrombolysis and, 60
- acute kidney injury (AKI), 33.
See also rhabdomyolysis
 classification system, 35–8
 renal replacement therapy for, 33
- Acute Kidney Injury Network (AKIN), 33
- acute liver failure (ALF)
 case study for, 40–1
 classification of, 41–2
 coagulation issues, 45
 definition, 40
- extra-corporeal techniques, 46
 fluid resuscitation with, 43–4
 ICP monitoring for, 40–1
 infection risks, 45
 management of, 43
 MAP and, 40–1
 MOF and, 42
 paracetamol toxicity, 42
 referral to specialist centres, 42
- renal replacement therapy for, 40–1
- system functionality with, 43–6
 cardiovascular, 43–4
 neurological, 44–5
 renal, 45
 respiratory, 44
- transplant criteria for, 44, 45–6
 ventilation, 44
- acute lung injury (ALI)
 ARDS and, 141, 144
 burn trauma and, 20
 case study for, 141–4
 CTPA for, 142
 PEEP and, 143–5
 surgical complications from, 144–5
 transpulmonary pressure and, 143–4
- Acute Physiology and Chronic Health Evaluation (APACHE), 331–2
- acute respiratory distress syndrome (ARDS), 20, 44, 120
 acute lung injury and, 141, 144
 definitions of, 141
 evidence-based strategies for, 122
 pathogens associated with, 267
 pulmonary
 thromboembolism and, 138–9

- acute respiratory failure, ILD
 and, 127–9
 immunosuppression for, 128
 ventilatory support for,
 128–9
- acute traumatic coagulopathy
 (ATC), 195–7
 antifibrinolytic drugs for,
 196–7
 bedside testing of, 195–6
 damage control resuscitation
 for, 197–8
 hyperfibrinolysis and,
 196–7
 ROTEM for, 195–6
 TEG for, 195–6
- acutely ill children,
 management of. *See also*
 paediatric septic shock
 case study for, 309–11
 referral of, 313
- adrenal crisis, clinical features
 of, 213
- adrenal insufficiency, 212–14
 biochemistry results, 211
 causes of, 213–14
 clinical features of, 212–14
 investigation results, 212
 secondary, 214
 TB and, 214
- AIH. *See* acute immune
 hepatitis
- AIP. *See* acute interstitial
 pneumonitis
- airway control and
 management
 for acute ischaemic stroke, 61
 case study for, 239–40
 Difficult Airway Society
 guidelines for, 243
 in eclampsia, 234
 failed intubation in, 242–5
 GCS for, 239
 hypoxaemia, 242
 laryngoscopy in, 245
 LMA and, 239–40, 245
 planning with, 240–2
 with polytrauma, 10–11
 prediction of, 240–2
 preoxygenation in, 242
- AIS. *See* acute ischaemic stroke
- AKI. *See* acute kidney injury
- AKIN. *See* Acute Kidney Injury
 Network
- alcoholic liver disease (ALD)
 case study for, 329–30
- Child-Pugh Score for,
 331–2
- clinical presentation of, 330,
 332
- complications from, 330
- ICU admission for, 330–1
- incidence rates of, 329
- MELD system and, 331–2
- organ transplants as a result
 of, 332
- severity of illness assessment,
 331–2
- specialist referrals with, 332
- ALF. *See* acute liver failure
- alfentanil, 1, 26, 33–4, 167, 232
- ALI. *See* acute lung injury
- American Burn Association
 (ABA), 21
- American Thoracic Society
 (ATS), 129
- aminophylline, 112
- amiodarone, 170
- amitriptyline toxicity, 168–9
- amphoterecin, 18, 22–3
- anabolic steroid therapy.
See also oxandrolone
 for burn trauma, 22
 for sepsis, 30–1
- anaesthetic volatile agents, 112
- aneurysmal subarachnoid
 haemorrhage (aSAH)
 case study, 65–6
 complications, 71–2
 delayed ischaemic deficit,
 71
 hydrocephalus, 71
 hyperglycaemia, 71
 hyperthermia, 71
 hyponatraemia, 72
 neurogenic pulmonary
 oedema, 72
 rebleeding, 71
 seizures, 72
- diagnosis of, 68–9
 imaging for, 69
- epidemiology, 66–8
- incidence rates, 65
- management of, 69–71
 with anti-fibrinolytic
 drugs, 71
 through clipping, 69–70
 through coiling, 69–70
 ISAT trial, 69–70
- presentation, 66–8
- WFNS grading scale, 68
- antibiotics, for pneumonia, 120
- anti-fibrinolytic drugs
 for acute trauma
 coagulopathy, 196–7
 for polytrauma, 13
 for subarachnoid
 haemorrhage, 71
- antimicrobial therapy, for
 necrotising soft tissue
 infections, 175–6
- antiplatelet therapy, for acute
 ischaemic stroke, 63
- APACHE. *See* Acute
 Physiology and Chronic
 Health Evaluation
- APP. *See* abdominal perfusion
 pressure
- aquacel, 22
- ARDS. *See* acute respiratory
 distress syndrome
- aSAH. *See* aneurysmal
 subarachnoid
 haemorrhage
- aspirin therapy, 63. *See also*
 antiplatelet therapy
- asthma, ventilation for
 case study for, 107
 disease characteristics of,
 108–9
 follow-up after discharge,
 113
 hypercarbia and, 110
 identification of, 108–9
 incidence rates for, 107
 non-invasive ventilation role
 of, 113
 pathophysiology of, 109
 treatment strategies,
 109–12
 with aminophylline, 112
 with anaesthetic volatile
 agents, 112
 with bronchodilators,
 111
 dynamic hyperinflation,
 110
 with intravenous beta-
 agonists, 112
 invasive ventilation,
 109–10
 with ketamine, 110, 112
 with magnesium, 112
 with metered dose
 inhalers, 111
 with nebulisers, 111
 with preoxygenation, 110
 steroid therapy, 111–12

- ATC. *See* acute traumatic coagulopathy
 atorvastatin, 33
 atovaquone, 183
 ATS. *See* American Thoracic Society
 avoidance of venous obstruction, 77
- BAL. *See* bronchoalveolar lavage
 barbiturate coma, 80
 barbiturates, 214
 basimixilab, 41
 bendroflumazide, 33
 benzodiazepines, 300, 339
 bilirubin, 188. *See also* jaundice
 bioimpedance cardiography, 288
 bioelectance, 288
 blood loss. *See* massive haemorrhage
 blood pressure management
 acute ischaemic stroke and, 59–62
 with pre-eclampsia/eclampsia, 232
 after traumatic brain injury, 76
 blood stream infections (BSIs), 256
 Bogota bag, 100
 brain injury. *See* acute brain injury; traumatic brain injury
 Brain Trauma Foundation (BTF), 77
 British Thoracic Society (BTS), 108, 120, 127
 bronchoalveolar lavage (BAL), 270
 bronchodilators, 111
 bronchoscopy, burn trauma and, 20
 BSIs. *See* blood stream infections
 BTF. *See* Brain Trauma Foundation
 BTS. *See* British Thoracic Society
 burn trauma
 anabolic steroid therapy for, 22
 ARDS, 20
 blood pressure and, 17
 bronchoscopy and, 20
 case study, 17–19
 circulation issues, 20–1
 emergency fasciotomy for, 17
 fluid resuscitation with, 20–1
 American Burn Association guidelines, 21
 crystalloid, 20–1
 hyperglycaemia, 22
 incidence rates of, 17
 infection complications with, 22–3
 lung injury and, 20
 nutrition intervention for, 21–2
 SDD regimen, 18, 22–3
 SIRS and, 21–2
 transfusions with, 21
 ventilation interventions, 20
 wound care and, 22
- CAM-ICU. *See* Confusion Assessment Method for intensive care unit
 CAP. *See* community-acquired pneumonia
 carbon dioxide control, with TBI, 76
 carbon dioxide rebreathing, 289
 cardiac arrest, post-resuscitation management
 care algorithms, 1–7
 out of hospital cardiac arrests (OHCA)
 coronary angiography after, 4–5
 CT scans and, 1–2, 7
 ECG and, 1–2
 EEG and, 1–2
 hypothermia and, 2–4
 incidence rates for, 1
 intra-aortic balloon pump after, 5
 neurological prognostication after, 5–7
 normothermia and, 2, 4
 somatosensory evoked potentials for, 1–2, 6–7
 targeted temperature management, 2–4
 treatment withdrawal and, 2
 cardiac output monitoring
 bioimpedance, 288
 bioelectance, 288
 carbon dioxide rebreathing and, 289
 case study for, 284–5
 clinical assessment in, 285
 electrical velocimetry in, 288
 lithium dilution, 287
 oesophageal Doppler, 286–7
 photoplethysmography, 289
 pulmonary artery catheter, 286
 pulse contour analysis, 287, 288
- cardiogenic shock
 case study for, 158–61
 causes of, 158
 classification of, 159–65
 diagnosis of, 158
 incidence, 158
 intra-aortic balloon pump for, 162–3
 left-ventricular assist device and, 163–4
 management of, 158, 161–4
 SOFA scoring and, 158, 161
 V-A ECMO devices for, 158, 161–4
 contraindications for, 162
 methods of, 163
 NICE guidelines, 162
- cardiography. *See* bioimpedance cardiography
 cardiovascular monitoring
 acute liver failure and, 43–4
 for sepsis, 30
 care bundles, 27–9
 catabolism, 225
 catheter related blood stream infection (CR-BSI), 256
 care bundle, 261–4
 causative factors, 257
 definition, 258, 261–4
 infection rate run chart, 261–2
 pathogenesis of, 257
 prevention of, 259–60
 treatment of, 258–9
- ceftazidime, 271
 central line associated blood stream infection (CLA-BSI), 256
 care bundle, 261–4
 definition, 258, 261–4
 infection rate run chart, 261–2
 pathogenesis of, 257
 prevention of, 259–60
 treatment of, 258–9

- central pontine myelinolysis, 207–8
 central V-A ECMO, 163–4
 central venous catheter
 infections. *See also* catheter related blood stream infection; central line associated blood stream infection
 asepsis and, 260
 case study for, 256
 catheters
 care management
 strategies, 260–2
 insertion site selection, 260
 replacement strategies, 262
 type, 260
 education about, 260
 sterile precautions, 260–2
 cerebral metabolic rate for oxygen (CMRO₂), 76, 77
 cerebral oedema, 207–8
 cerebral oxygenation, 76
 Cerebral Performance Category (CPC) grading, after out of hospital cardiac arrest, 5–6
 cerebral perfusion pressure (CPP), 40–1
 traumatic brain injury and, 75–6
 cerebral salt wasting syndrome (CSW), 72
 cerebral venous and sinus thrombosis (CVST), 52
 cerebrospinal fluid (CSF), 11, 75–6
 cervical spine injury, 322. *See also* clearance of the cervical spine
 Child-Pugh Scores, 86, 331–2
 chlorhexidine, 26
 cholecystectomy, 95–6
 chronic liver disease, 85
 chronic thromboembolic pulmonary hypertension (CTEPH), 131, 133
 ciprofloxacin, 271
 cirrhosis. *See* alcoholic liver disease
 CLA-BSI. *See* central line associated blood stream infection
 clearance of the cervical spine
 case study for, 322–3
 CT scanning in, 324–7
 MRI for, 326–7
 practice audit standards, 325
 clindamycin, 18
 Clostridial myonecrosis, 172
 CMRO₂. *See* cerebral metabolic rate for oxygen
 coagulation. *See also* anti-fibrinolytic drugs
 with acute liver failure, 45
 Cold Shock, 311–12
 colloid fluid resuscitation, 12
 colomycin, 18
 community acquired-MRSA, 119
 community-acquired pneumonia (CAP), 115
 computerised tomography (CT)
 in clearing of the cervical spine, 324–7
 for critical care patients, 294–5
 for out of hospital cardiac arrest, 1–2, 7
 for polytrauma, 13
 computerised tomography angiography (CTA), 69
 Confusion Assessment Method for intensive care unit (CAM-ICU), 296–7
 continuous renal replacement therapy (CRRT), 37
 for pulmonary thromboembolism, 139
 continuous venovenous haemodiafiltration (CVVHD), 26
 COP. *See* cryptogenic organising pneumonia
 coronary angiography, after out of hospital cardiac arrest, 4–5
 co-trimoxazole, 180
 for pneumocystis pneumonia treatment, 181–3
 Coxiella burnetii, 119
 CPC grading. *See* Cerebral Performance Category grading
 CPP. *See* cerebral perfusion pressure
 CR-BSI. *See* catheter related blood stream infection
 creatinine, 45
 critical care patients
 admittance criteria
 case study for, 316–17
 frailty assessment in, 318
 guidance on, 317–18
 treatment limitations as part of, 319–20
 surgical management of abdominal wound care management, 293–4
 case study for, 291–2
 CT scanning in, 294–5
 surgical decision making for, 292–3
 CRRT. *See* continuous renal replacement therapy
 cryptogenic organising pneumonia (COP), 125
 crystalloid fluids
 for burn trauma, 20–1
 for polytrauma, 12
 CSF. *See* cerebrospinal fluid
 CSW. *See* cerebral salt wasting
 CT. *See* computerised tomography
 CT pulmonary angiogram (CTPA), 116, 142
 CTA. *See* computerised tomography angiography
 CTEPH. *See* chronic thromboembolic pulmonary hypertension
 CTPA. *See* CT pulmonary angiogram
 CVST. *See* cerebral venous and sinus thrombosis
 CVVHD. *See* continuous venovenous haemodiafiltration
 cyroheptadine, 339
 damage control surgery, for polytrauma, 14
 dantrolene, 338, 340
 dapsone, 183
 DAS. *See* Difficult Airway Society
 DCD. *See* donation after circulatory death
 DCI. *See* delayed ischaemic deficit
 de novo interstitial lung disease, 124

- death. *See* organ transplantation
- decompressive craniectomy, 62
 for traumatic brain injury management, 80
- delayed ischaemic deficit (DCI), 71
- delirium
 case study for, 297–8
 clinical presentation of, 296
 hyperactive, 296–7
 hypoactive, 296–7
 in ICU, 298
 CAM-ICU scoring, 296–7
 medication review, 299–300
 precipitating factors, 298–9
 therapeutic options, 300–1
 pathophysiology of, 297
 subtypes of, 296–7
- dexamethasone, 297–8
- DHI. *See* dynamic hyperinflation
- diabetic ketoacidosis (DKA), 202–3
 case study for, 201–2
 clinical presentation of, 202–3
 critical care admission for, 204
 diagnosis of, 202–3
 fluid and electrolyte deficits, 203
 insulin administration for, 205
 management of, 203–5
 pathophysiology of, 202–3
 potassium replacement for, 205
 volume recirculation for, 204–5
- diazepam, 51–2, 54–5
- Difficult Airway Society (DAS), 243
- diffuse axonal injury, 75
- dilators. *See* specific pulmonary dilators
- dilutional hyponatraemia, 337
- DKA. *See* diabetic ketoacidosis
- dobutamine, 30
- donation after circulatory death (DCD), 306–7
- dynamic hyperinflation (DHI), 110
- dysphagia, 61
- EAPCI. *See* European Association for Percutaneous Cardiovascular Interventions
- early goal-directed therapy (EGDT), 29
- ECG. *See* electrocardiogram
- eclampsia. *See* pre-eclampsia/eclampsia
- ECMO. *See* extracorporeal membrane oxygenation
- ecstasy. *See* MDMA toxicity
- EEG. *See* electroencephalogram
- EG toxicity. *See* ethylene glycol toxicity
- EGDT. *See* early goal-directed therapy
- electrical velocimetry, 288
- electrocardiogram (ECG), for
 out of hospital cardiac arrest, 1–2
- electroencephalogram (EEG)
 in acute brain injury neuromonitoring, 281–2
 for out of hospital cardiac arrest, 1–2
- electrolyte replacement, with
 HHS, 206
- encephalopathy. *See* hepatic encephalopathy
- endocrine emergencies
 adrenal crisis, 214–16
 aetiology of, 214–15
 clinical features of, 213
 clinical investigation of, 215
 cortisol production, 215
 diagnosis of, 215
 emergency treatment of, 215–16
 adrenal insufficiency, 212–14
 biochemistry results, 211
 causes of, 213–14
 clinical features of, 212–14
 investigation results, 212
 secondary, 214
 TB and, 214
 case study for, 210–12
- endoscopic therapy, for variceal haemorrhage, 87–8
- enoxaparin, 26
- enteral nutrition, 31
- enteral pulmonary dilators, 135
- ethylene glycol (EG) toxicity, 218
 case study for, 218–19
 diagnosis of, 219–20
 through ingestion, 220
 management and treatment of, 222
 raised anion gap acidosis and, 220–3
 symptoms of, 220–2
- etomidate, 214, 216
- European Association for
 Percutaneous Cardiovascular Interventions (EAPCI), 5
- exploratory laparotomy, 14
- extracorporeal membrane oxygenation (ECMO), 20
- extradural haematoma, 75
- Face Arm Speech Test (FAST) scale, 58–9
- failed intubation, 242–5
- fasciotomies, for burn trauma, 17
- FAST scale. *See* Face Arm Speech Test scale
- fibreoptic bronchoscopy (FB), 247–8
- Fick principle, 289
- fluconazole, 214, 297–8
- fluid resuscitation
 with acute liver failure, 43–4
 with acute traumatic coagulopathy, 197–8
 with burn trauma, 20–1
 American Burn Association guidelines, 21
 crystalloid, 20–1
 paediatric septic shock and, 311
 for polytrauma, 11–12
 colloid, 12
 crystalloid, 12
 hypotensive, 11–12
 low volume, 11–12
 sepsis and, 29–30
 for variceal haemorrhage, 84–5
- fluoroquinolone, 176, 271
- fomepizole, 222
- foot care, 208
- Fournier's gangrene, 172

- fungal infections. *See also*
 pneumonia
 case study for, 179–81
 pneumocystis pneumonia (PCP), 128
 cell biology for, 182
 clinical presentation of, 182
 imaging in, 182
 mortality rates for, 182
 treatment for, 131, 181–3
 pneumocystitis jirovecii pneumonia, 181–3
 renal dialysis and, 179
- GCS. *See* Glasgow Coma Scale
- GDC. *See* Guglielmi detachable coil
- gestational thrombocytopenia, 236–7
- GGS. *See* Group G β -haemolytic streptococci
- Glasgow Coma Scale (GCS), 9, 239, 276–8
- glucose emergencies
 DKA, 202–3
 case study for, 201–2
 clinical presentation of, 202–3
 critical care admission for, 204
 diagnosis of, 202–3
 fluid and electrolyte deficits, 203
 insulin administration for, 205
 management of, 203–5
 pathophysiology of, 202, 203
 potassium replacement for, 205
 volume recirculation for, 204–5
- HHS, 205–8
 blood glucose normalisation and, 207
 cerebral complications from, 207–8
 fluid and electrolyte replacement, 206
 foot care with, 208
 serum osmolality normalisation, 207
 severity assessment, 206
 thromboembolic disease from, 207
- glucose levels
 acute ischaemic stroke and, 59–62
 HHS and, 207
 refeeding syndrome and, 226–7
- glycoaldehyde, 220
- glycolic acid, 220
- glyoxylic acid, 220
- gram-negative bacilli, 119
- grey matter and white matter differentiation (GWR), 7
- Group G β -haemolytic streptococci (GGS), 155
- Guglielmi detachable coil (GDC), 69–70
- GWR. *See* grey matter and white matter differentiation
- haematomas, 75
- haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, 233, 235–6
- haemophilus influenzae, 119
- haemorrhage. *See* massive haemorrhage
- haloperidol, 297–8, 300
- HELLP syndrome. *See* haemolysis, elevated liver enzymes, low platelets syndrome
- hemispanectomy, 62
- heparin, 45
- LMWH, 79
- hepatic encephalopathy. *See also* acute liver failure
 Conn Score for, 40–1
- hepatitis
 acute jaundice, 190–1
 autoimmune hepatitis, 191–2
 treatment of, 191–2
- HES. *See* hydroxyethyl starch
- HFOV. *See* high frequency oscillatory ventilation
- HHS. *See* hyperosmolar hyperglycaemic state
- high frequency oscillatory ventilation (HFOV), 20
- high frequency percussive ventilation, 20
- HIV-related diseases, pneumocystis pneumonia, 128
- Human Tissue Act 2004, (HTA), 306
- hydralazine, 234
- hydrocephalus, 71
- hydrocortisone, 26
- hydroxyethyl starch (HES), 12, 29
- hyoscine butylbromide, 298
- hyperactive delirium, 296–7
- hypercarbia, 110
- hyperfibrinolysis, 196–7
- hyperglycaemia
 acute ischaemic stroke and, 22, 62
 burn trauma and, 22
 subarachnoid haemorrhage and, 71
 traumatic brain injury and, 80
- hyperosmolar hyperglycaemic state (HHS), 205–8
 blood glucose normalisation and, 207
 cerebral complications from, 207–8
 fluid and electrolyte replacement, 206
 foot care with, 208
 serum osmolality normalisation, 207
 severity assessment, 206
 thromboembolic disease from, 207
- hyperpyrexia
 MDMA toxicity and, 335, 337–8
 activated charcoal therapy, 339
 case study for, 335–6
 clinical presentation of, 336–7
 differentiation of syndromes, 338
 hyperthermia and, 337
 management of, 339–41
 pharmacology of, 336
 serotonin syndrome, 338–9
- hypertension
 acute ischaemic stroke and, 61–2
 with pre-eclampsia, 234–5
- hyperthermia
 MDMA toxicity and, 337
 subarachnoid haemorrhage and, 71

- hypoactive delirium, 296–7
 hyponatraemia
 dilutional, 337
 legionella pneumophila and, 119
 subarachnoid haemorrhage and, 72
 hypophosphataemia, refeeding syndrome and, 227–8
 hypotension, acute ischaemic stroke and, 62
 hypotensive fluid resuscitation for polytrauma, 11–12
 for traumatic brain injury, 77
 hypothermia
 ILCOR guidelines, 3–4
 out of hospital cardiac arrest and, 2–4
 targeted temperature management and, 2–4
 in traumatic brain injury management, 80
 hypoxaemia
 acute ischaemic stroke and, 61
 airway management and, 242
 preoxygenation and, 242
 IABP. *See* intra-aortic balloon pump
 ICP. *See* intracranial pressure
 ICUs. *See* intensive care units
 idiopathic thrombocytopenic purpura, 236–7
 IE. *See* infective endocarditis
 ILCOR. *See* International Liaison Committee on Resuscitation
 ILD. *See* interstitial lung disease
 immunosuppression
 with ILD, 128
 with pneumonia, 119
 IMPACT model. *See* International Mission for Prognosis and Analysis of Clinical Trials model
 infection risks. *See also* fungal infections
 with acute ischaemic stroke, 63
 acute liver failure and, 45
 with burn trauma, 22–3
 with renal dialysis, for fungal infections, 179
 infective endocarditis (IE)
 case study for, 152–5
 causative organisms for, 156
 clinical presentation, 152, 155
 Duke Criteria for, 155
 GGS and, 155
 left-sided, 156–7
 right-sided, 156–7
 systemic embolisation risks, 156
 transthoracic echocardiography for, 156
 treatment strategies for, 156–7
 inhaled iloprost, 136
 inhaled pulmonary vasodilators, 136
 insulin, DKA and, 205
 intensive care units (ICUs)
 acute ischaemic stroke and, admission indications for, 59–60
 alcohol-related liver disease admissions, 330–1
 delirium in, 298
 CAM-ICU, 296–7
 medication review, 299–300
 precipitating factors for, 298–9
 therapeutic options, 300–1
 pneumonia management, 121–2
 tricyclic antidepressant overdose management in, 167–8
 variceal haemorrhage support in, 89
 INTERMACS classification, of cardiogenic shock, 159, 160–5
 International Liaison Committee on Resuscitation (ILCOR), 3–4
 International Mission for Prognosis and Analysis of Clinical Trials (IMPACT) model, 81
 International Subarachnoid Aneurysm Trial (ISAT), 69–70
 interstitial lung disease (ILD)
 acute interstitial pneumonitis and, 125
 with acute respiratory failure, 127–9
 immunosuppression with, 128
 non-invasive ventilation for, 129
 ventilatory support for, 128–9
 case study for, 124–5
 clinical presentation, 124
 cryptogenic organising pneumonia and, 125
 de novo, 124
 diagnostic investigations for, 126–7
 five common causes of, 127–8
 idiopathic pulmonary fibrosis and, 125
 imaging in, 126–7
 known established, 124
 management of, 126
 pneumocystis pneumonia and, 128
 rapidly progressive, 125
 tuberculosis and, 128
 intra-abdominal hypertension (AIP)
 abdominal perfusion pressure and, 102
 Bogota bag and, 100
 case study for, 99–100
 clinical presentation, 100, 101
 complications for, 102–3
 discovery of, 98
 imaging in, 101–2
 management strategies for, 103
 risk factors for, 100–1
 surgical treatment for, 103
 intra-aortic balloon pump (IABP)
 for cardiogenic shock, 162–3
 after out of hospital cardiac arrest, 5
 intracranial pressure (ICP)
 with acute ischaemic stroke, 60
 with acute liver failure, 40–1
 ketamine and, 11

- intracranial pressure (ICP)
 (cont.)
 in neuromonitoring for acute brain injury, 276
 traumatic brain injury and, 75–7, 79
 intravenous beta-agonists, 112
 intravenous fluid therapy, for rhabdomyolysis, 37
 intravenous immunoglobulin (IVIG) therapy, 176–7
 intravenous pulmonary dilators, 135
 ISAT. *See* International Subarachnoid Aneurysm Trial
 IVIG therapy. *See* intravenous immunoglobulin therapy
- jaundice, acute
 autoimmune hepatitis, 191–2
 treatment of, 191–2
 case study for, 185–8
 classification of, 190–2
 clinical history of, 189–90
 clinical investigations for, 190–1
 clinical presentation of, 185
 diagnosis of, 185
 criteria in, 192
 evaluation of, 188
 hepatitis viruses and, 190–1
 LFTs for, 185–6
 non-invasive liver screen for, 186
 physical examination for, 190
- ketamine, 11, 55
 in asthma treatment, 110, 112
 ketoconazole, 214
 Klebsiella, 119
 known established interstitial lung disease, 124
- Lance-Adams syndrome, 6
 laparotomies. *See* exploratory laparotomy
 laryngeal mask airway (LMA), 239–40, 245
 left ventricular mechanical assist devices (L-VAD), 163–4
- left-sided infective endocarditis, 156–7
 legionella pneumophila, 119
 levetiracetam, 63
 LFTs. *See* liver function tests
 lignocaine, 170
 lipid rescue therapy, 170
 lithium dilution, 287
 liver disease. *See* alcoholic liver disease
 liver function tests (LFTs), 185–6
 LMA. *See* laryngeal mask airway
 LMWH. *See* low-molecular weight heparin
 lorazepam, 51–2
 low-molecular weight heparin (LMWH), 79
 low-volume fluid resuscitation, for polytrauma, 11–12
 Lund strategies, in traumatic brain injury management, 77
 L-VAD. *See* left ventricular mechanical assist devices
- Maastricht classification.
 See donation after circulatory death
 mafenide acetate, 22
 magnesium
 in asthma treatment, 112
 in eclampsia treatment, 234–5
 in tricyclic antidepressant overdose, 170
 magnetic resonance angiography (MRA), 69
 magnetic resonance imaging (MRI), 326–7
 mannitol, 36
 MAP. *See* mean arterial pressure
 MARS. *See* molecular absorbent recirculating system
 massive haemorrhage
 acute traumatic
 coagulopathy, 195–7
 anti-fibrinolytics for, 196–7
 bedside testing of, 195–6
 damage control
 resuscitation for, 197–8
- hyperfibrinolysis and, 196–7
 ROTEM for, 195–6
 TEG for, 195–6
 case study for, 194–5
 radiological control of, 199
 surgical control of, 199
 maximum sterile barrier (MSB) precautions, 260–2
 MDMA toxicity, 335
 activated charcoal therapy, 339
 clinical presentation of, 336–7
 hyperthermia and, 337
 management of, 339–41
 pharmacology of, 336
 mean arterial pressure (MAP)
 acute liver failure and, 40–1
 burn trauma and, 17
 septic shock and, 29
 mechanical assist devices
 left-ventricular assist device, 163–4
 V-A ECMO, 158, 161–4
 central, 163–4
 contraindications for, 162
 NICE guidelines, 162
 peripheral, 163
 mechanical ventilation (MV), 147
 MELD system. *See* Model for End-stage Liver Disease system
 meningococcal disease. *See* septic shock
 Mental Capacity Act 2005, 319
 meropenem, 18, 176, 271
 MERS. *See* Middle East Respiratory Virus
 methicillin-resistant *Staphylococcus aureus* (MRSA), 119
 CA-MRSA type, 119
 necrotising soft tissue infections and, 176
 metronidazole, 26
 midazolam, 55, 298
 Middle East Respiratory Virus (MERS), 120
 mixed delirium, 296–7
 MMF. *See* mycophenolate mofetil
 Model for End-stage Liver Disease (MELD) system, 331–2

- Modified Glasgow Score, 94–5
 MOF. *See* multi-organ failure
 molecular absorbent
 recirculating system
 (MARS), 46
 Monroe-Kellie doctrine, 76
 Moraxhella catarrhalis, 119
 MRA. *See* magnetic resonance
 angiography
 MRI. *See* magnetic resonance
 imaging
 MRSA. *See* methicillin-resistant
 Staphylococcus aureus
 MSB precautions. *See*
 maximum sterile
 barrier precautions
 multi-organ failure (MOF), 42
 MV. *See* mechanical ventilation
 mycophenolate mofetil (MMF),
 41
 mycoplasma pneumoniae, 119
 myoglobin, 35
- National Institute for Health
 and Care Excellence
 (NICE)
 refeeding syndrome
 management guidelines,
 229
 V-A ECMO device
 guidelines, 162
 nebulisers, 111
 necrosectomy, 95–6
 necrotising myositis, 172
 necrotising soft tissue
 infections
 aetiology of, 172
 case study for, 172–4
 clinical considerations with,
 174–5
 clinical presentation, 172
 Clostridial myonecrosis,
 172
 Fournier's gangrene, 172
 MRSA and, 176
 necrotising myositis, 172
 public health considerations,
 177
 scope of, 172
 spontaneous gangrenous
 myositis, 172
 therapeutic approaches to
 antimicrobial, 175–6
 immunoglobulin, 176–7
 Type 1 necrotising fasciitis,
 172
- Type II necrotising fasciitis,
 172
 negative pressure wound
 therapy (NPWT), 103
 neurogenic pulmonary oedema
 (NPE), 72
 neurological functioning
 with acute liver failure,
 44–5
 after out of hospital cardiac
 arrest, 5–7
 neuromonitoring, for acute
 brain injury. *See* acute
 brain injury
 neurone specific enolase (NSE),
 7
 NICE. *See* National Institute for
 Health and Care
 Excellence
 nimodipine, 71
 nitric oxide, 136
 NIV. *See* non-invasive
 ventilation
 non-invasive liver screen, 186
 non-invasive ventilation (NIV),
 113, 129
 case study for, 148–9
 definitions of, 147
 extubation and, 149–50
 mechanical ventilation and,
 147
 normothermia, 2, 4
 NPE. *See* neurogenic
 pulmonary oedema
 NPWT. *See* negative pressure
 wound therapy
 NSE. *See* neurone specific
 enolase
 nutrition
 burn trauma and, 21–2
 enteral, 31
 parenteral, 31
 sepsis and, 31
- oesophageal Doppler probe,
 286–7
 OHCA. *See* out of hospital
 cardiac arrest
 olanzapine, 298
 omeprazole, 26
 organ transplantation
 acute liver failure and, 44–6
 ALD and, 332
 after death
 case study for, 303–4
 consent for, 306
- DCD classification,
 306–7
 definition of death, 306
 emotional responses to,
 305
 historical development of,
 305
 Human Tissue Act 2004,
 306
 organ optimisation before
 retrieval, 307
 osmotherapy, in traumatic
 brain injury
 management, 80–1
 out of hospital cardiac arrest
 (OHCA)
 cerebral performance
 category (CPC) grades,
 5–6
 coronary angiography after,
 4–5
 CT scans and, 1–2, 7
 ECG and, 1–2
 EEG and, 1–2
 hypothermia and, 2–4
 incidence rates for, 1
 intra-aortic balloon pump
 after, 5
 neurological prognostication
 after, 5–7
 normothermia and, 2, 4
 ROSC after, 1–2
 somatosensory evoked
 potentials for, 1–2,
 6–7
 targeted temperature
 management, 2–4
 withdrawal of life sustaining
 therapies and, 2
 overdose management, tricyclic
 antidepressant, 166
 alfentanil use and, 167
 amitriptyline toxicity and,
 168–9
 assessment of, 169–70
 case study for, 166
 features of, 169
 in ICUs, 167–8
 initial management
 strategies, 167
 pharmacokinetics of,
 169–71
 propofol use and, 167
 therapy strategies, 170
 oxandrolone, 18, 22
 oxycodone, 298

- oxygen management. *See also*
 cerebral oxygenation;
 extracorporeal
 membrane oxygenation;
 preoxygenation;
 venous-arterial
 extracorporeal
 membrane oxygenation;
 veno-venous extra
 corporeal membrane
 oxygenation
 acute ischaemic stroke and,
 59–61
 CMRO₂, 76–7
- PAC. *See* pulmonary artery
 catheter
- PAE. *See* pulmonary
 endarterectomy
- paediatric intensive care units
 (PICUs)
 acutely ill children,
 management of
 case study for, 309–11
 centralisation of, 313
 referral criteria, 314
 paediatric septic shock
 ‘Cold Shock,’ 311–12
 haemodynamic response, 312
 pathophysiology of, 311–12
 resuscitation goals, 311
 treatment guidelines, 313
 ‘Warm Shock,’ 312
- pancreatitis
 case study for, 91–2
 clinical presentation of, 91
 imaging in, 95
 mortality risk assessment, 94
 risk stratification with, 93–4
 severity assessment, 93–5
 Modified Glasgow Score
 in, 94–5
 Ranson Score in, 94
 surgical treatment for, 95–6
 with cholecystectomy, 95–6
 with necrosectomy, 95–6
- pandemic influenza, 120
- Panton-Valentine leukocidin
 (PVL), 119
- paracetamol toxicity, 42
- parenteral nutrition, 31
- PCP. *See* pneumocystis carinii
 pneumonia
- PDT. *See* percutaneous
 dilatational
 tracheostomy
- PE. *See* pulmonary embolus
- PEEP. *See* positive end
 expiratory pressure
- pentamidine, 183
- percutaneous dilatational
 tracheostomy (PDT),
 247, 253–4
 fiberoptic bronchoscopy for,
 247–8
- peripheral V-A ECMO, 163
- phaeochromocytoma, 234
- phenobarbitone, 51–2, 55
- phenytoin, 51–2, 54–5, 170, 214
- photoplethysmography, 289
- PICCO. *See* pulse index
 contour cardiac output
- PICUs. *See* paediatric intensive
 care units
- piperacillin, 26, 148, 271
- plasma transfusions, with
 polytrauma, 12–13
- platelet transfusions, with
 polytrauma, 12–13
- pMDIs. *See* pressurised
 metered-dose inhalers
- pneumocystis carinii
 pneumonia (PCP), 128,
 181–3
 cell biology for, 182
 clinical presentation of, 182
 imaging in, 182
 mortality rates for, 182
 treatment for, 182–3
 with co-trimoxazole,
 181–3
- pneumocystitis jirovecii
 pneumonia, 181–3
- pneumonia. *See also* ventilated
 associated pneumonia;
specific pneumonias
 antibiotic therapy, 120
 case study, 115–17
 community acquired
 pneumonia, 115
 complications, 121
 definition of, 117–18
 differential diagnosis, 118
 ICU management, 121–2
 immunosuppression issues,
 119
 initial investigations, 115
 microbiological testing for,
 120
 mortality of, 118
 organisms responsible for,
 118–19
- patient failure to improve,
 121
 risk prediction systems, 121
 SCAP score, 121
 severity assessment, 121
 viral causes of, 119–20
 ARDS, 120
 MERS, 120
 pandemic influenza, 120
 RSV, 119
 SARS, 120
- Pneumonia Severity Index
 (PSI), 121
- polymixin B, 22–3
- polytrauma
 airway control, 10–11
 anti-fibrinolytic drugs and,
 13
 clinical presentation, 9
 CT scans for, 13
 damage control surgery for,
 14
 definition, 9
 exploratory laparotomy for,
 14
 fluid resuscitation, 11–12
 colloid, 12
 crystalloid, 12
 hypotensive, 11–12
 low volume, 11–12
 ketamine and, 11
 long-term prognosis, 9
 transfusions and, 12–13
 of plasma and platelets,
 12–13
 red blood cells, 12
- positive end expiratory
 pressure (PEEP), 99,
 138–9, 142
 acute lung injury, 143–5
 potassium replacement, 205
 prednisolone, 111–12, 298
 pre-eclampsia/eclampsia
 airway management in, 234
 blood pressure and, 232
 blood results with,
 interpretation of, 236–7
 case study for, 232–3
 causes of, 236–7
 delivery planning, 235
 early warning scoring
 systems, 237
 HELLP syndrome and, 233,
 235–6
 hypertension management
 with, 234–5

- incidence rates for, 232
 magnesium treatment in, 234–5
 mortality from, causes of, 233–4
 phaeochromocytoma and, 234
 renal function with, 236
 seizures with, 235
 venous thromboembolism prevention and, 236
 pregabalin, 299–300
 preoxygenation
 airway control and, 242
 in asthma treatment, 110
 hypoxaemia and, 242
 pressurised metered-dose inhalers (pMDIs), 111
 primaquine, 183
 propofol, 1, 26, 33–4, 51, 55, 167
 prostacyclin, 136
 protected specimen brush (PSB) sampling, 270
 prothrombin time (PT). *See also* coagulation
 with acute liver failure, 45
 PSB sampling. *See* protected specimen brush sampling
 pseudomonas, 119
 PSI. *See* Pneumonia Severity Index
 PT. *See* prothrombin time
 PTE. *See* pulmonary thromboembolism
 pulmonary artery catheter (PAC), 134
 cardiac monitoring with, 286
 pulmonary embolus (PE), 116
 pulmonary endarterectomy (PAE), 131–2
 pulmonary thromboembolism (PTE)
 ARDS and, 138–9
 case study for, 131–2
 chronic pulmonary hypertension and, 131, 133
 continuous renal replacement therapy for, 139
 definition, 132
 haemodynamic physiology and management, 133–7
 mechanical support in, 137
 PAC and, 134
 pulmonary vascular resistance calculation, 134
 right ventricular contractility, 136–7
 right ventricular overload, 133–4
 right ventricular perfusion, 137
 right ventricular preload, 136
 with vasodilators, 134–6.
 See also specific dilators
 ventricular interdependence, 133
 long-term prognosis, 139
 reperfusion pulmonary oedema, 138–9
 respiratory management, 137–9
 ventilation strategies for, 138
 VV-ECMO and, 138–9
 WHO classification of causes, 132
 pulmonary vascular resistance (PVR), 134
 pulse contour analysis, 287
 uncalibrated, 288
 pulse index contour cardiac output (PICCO), 26
 PVL. *See* Panton-Valentine leukocidin
 PVR. *See* pulmonary vascular resistance
 pyridoxine, 222
 RAAS. *See* renin-angiotensin-aldosterone system
 raised anion gap acidosis, 220–3
 ramipril, 33
 Ranson Score, 94
 rapidly progressive interstitial lung disease, 125
 reactive oxygen species (ROS), 36
 rebleeding complications, with subarachnoid haemorrhage, 71
 red blood cell transfusions, with polytrauma, 12
 refeeding syndrome, 225
 case study for, 225–6
 clinical presentation of, 227–8
 management of, 229
 manifestations of, 229
 mortality rates, 228
 NICE guidelines for, 229
 pathophysiology of, 226–7
 glucose levels and, 226–7
 hypophosphataemia in, 227–8
 risk factors for, 230
 renal dialysis, fungal infection risks with, 179
 renal functioning
 with acute liver failure, 45
 with pre-eclampsia, 236
 renal replacement therapy (RRT)
 with acute liver failure, 40–1
 for rhabdomyolysis, 33, 37
 renin-angiotensin-aldosterone system (RAAS), 36
 reperfusion pulmonary oedema, 138–9
 respiratory syncytial virus (RSV), 119
 respiratory systems
 management
 with acute ischaemic stroke, 61
 with acute liver failure, 44
 with pulmonary thromboembolism, 137–9
 with thrombolysis, 61
 return of spontaneous circulation (ROSC), 1–2
 rhabdomyolysis (RM)
 case study, 33–4
 common causes of, 35
 diagnosis, 36
 intravenous fluid therapy for, 37
 management of, 36–7
 myoglobin and, 35
 pathophysiology of, 34–6
 renal replacement therapy for, 33, 37
 rifampicin, 214
 right-sided infective endocarditis, 156–7
 risk prediction systems, for pneumonia, 121
 RM. *See* rhabdomyolysis
 rocuronium, 110

- ROS. *See* reactive oxygen species
- ROSC. *See* return of spontaneous circulation
- Rosner strategies, in traumatic brain injury management, 77
- ROTEM. *See* thromboelastometry
- RRT. *See* renal replacement therapy
- RSV. *See* respiratory syncytial virus
- SARS. *See* severe acute respiratory syndrome
- SCAP. *See* Severe Community Acquired Pneumonia
- SDD regimen. *See* selective digestive decontamination regimen
- SE. *See* status epilepticus
- secondary adrenal insufficiency, 214
- seizures
- from acute ischaemic stroke, 63
 - aneurysmal SAH and, 72
 - with eclampsia, 235
 - traumatic brain injury management and, 81
- selective digestive decontamination (SDD) regimen, 18, 22–3, 271
- Sengstaken-Blakemore tube and, 85, 88
- sepsis
- additional supportive care, 31
 - cardiovascular monitoring, 30
 - care bundles, 27–9
 - definitions of, 26–7
 - diagnostic criteria for, 27
 - early goal-directed therapy for, 29
 - epidemiology, 26–7
 - fluid resuscitation and, 29–30
 - nutrition interventions and, 31
 - severe, 28
 - steroid therapy for, 30–1
 - vasoactive agents and, 30
- septic shock
- case study, 25–6
 - incidence rates, 25
 - management of, 29
 - MAP and, 29
 - paediatric
 - ‘Cold Shock,’ 311–12
 - haemodynamic response, 312
 - pathophysiology of, 311–12 - resuscitation goals, 311
 - treatment guidelines, 313
 - ‘Warm Shock,’ 312
 - pathophysiology of, 311–12
- sequential organ failure assessment (SOFA), 158, 161, 331–2
- serotonin syndrome, 338–9
- serum osmolality normalisation, 207
- severe acute respiratory syndrome (SARS), 120
- Severe Community Acquired Pneumonia (SCAP), 121
- severe sepsis, 28
- shock packs, 13
- SIADH. *See* syndrome of inappropriate antidiuretic hormone
- silver nitrate, 22
- silver sulfadiazine, 22
- SIRS. *See* systemic inflammatory response syndrome
- sodium valproate, 51, 55
- SOFA. *See* sequential organ failure assessment
- soft tissue infections. *See* necrotising soft tissue infections
- somatosensory evoked potentials (SSEP), for out of hospital cardiac arrest, 1–2, 6–7
- spontaneous gangrenous myositis, 172
- SSEP. *See* somatosensory evoked potentials
- ST elevation myocardial infarction (STEMI)
- out of hospital cardiac arrest
 - cerebral performance category grades, 5–6
 - coronary angiography after, 4–5
 - CT scans and, 1–2, 7
 - ECG and, 1–2
 - EEG and, 1–2
 - hypothermia and, 2–4
 - incidence rates for, 1
 - intra-aortic balloon pump after, 5
 - neurological prognostication after, 5–7
 - normothermia and, 2, 4
 - ROSC after, 1–2
 - somatosensory evoked potentials for, 1–2, 6–7
 - targeted temperature management, 2–4
 - withdrawal of therapy and, 2
- post-resuscitation care algorithms, 2–5
- status epilepticus (SE)
- anticonvulsive regime for, 50
 - case study, 49–51
 - causes of, 48
 - cerebral thrombosis and, 52
 - complications of, 51–2
 - critical care guidelines, 54–5
 - incidence rates for, 48
 - phases of, 48–9
 - seizure management, 51–2
- STEMI. *See* ST elevation myocardial infarction
- steroid therapy
- for asthma, 111–12
 - for burn trauma, 22
 - for sepsis, 30–1
- streptococcus pneumoniae, 118–19
- stroke. *See* acute ischaemic stroke
- subdural haematoma, 75
- suxamethonium, 110, 232, 239–40
- syndrome of inappropriate antidiuretic hormone (SIADH), 72
- systemic inflammatory response syndrome (SIRS), 21–2
- targeted temperature management
- hypothermia, 2–4
 - normothermia, 2, 4

- for out of hospital cardiac arrest, 2–4
- TARN. *See* Trauma Audit and Research Network
- tazobactam, 26, 148, 271
- TB. *See* tuberculosis
- TBI. *See* traumatic brain injury
- TCA. *See* tricyclic antidepressant
- TCD. *See* transcranial Doppler ultrasonography
- TEG. *See* thromboelastography
- teicoplanin, 271
- temperature management
- acute ischaemic stroke and, 59–61
 - hypothermia and, 2–4
 - normothermia and, 2, 4
 - with out of hospital cardiac arrest, 2–4
- terlipressin, 87
- thiamine treatment, for ethylene glycol toxicity, 222
- thiopentone, 55, 232, 239–40
- thromboelastography (TEG), 195–6
- thromboelastometry (ROTEM), 195–6
- thromboembolic disease, 207
- thrombolysis
- acute ischaemic stroke and, 60
 - airway and respiratory management, 61
- TIPS. *See* Transjugular Intrahepatic Portosystemic Shunt
- tobramycin, 18, 22–3
- tracheal anatomy, 248, 253–4
- tracheostomy
- case study for, 247–8
 - complications of, 250–1
 - fibreoptic bronchoscopy for, 247–8, 253–4
 - complications with, 253
 - equipment anatomy, 253
 - long term care for, 252
 - planning for, 250–1
 - safety guidelines, 250
 - techniques for, 248–52
 - choice of, 249–50
 - percutaneous, 249
 - surgical, 249
 - tube choice and, 252
- ventilated associated pneumonia and, 247
- TRALI. *See* transfusion-associated acute lung injury
- tramadol, 299–300
- tranexamic acid, 196–7
- transcranial doppler ultrasonography (TCD), 280
- transfusion triggers in, 79
- transfusion-associated acute lung injury (TRALI), 141
- transfusions
- with burn trauma, 21
 - with polytrauma, 12–13
 - of plasma and platelets, 12–13
 - red blood cells, 12
 - shock packs, 13
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), 85, 88
- transplantation. *See* organ transplantation
- transpulmonary pressure, 143–4
- transpulmonary thermolulution, 287
- transthoracic echocardiography (TTE), 156
- trauma, incidence rates, 9. *See also specific traumas*
- Trauma Audit and Research Network (TARN), 13
- trauma-induced coagulopathy. *See* acute traumatic coagulopathy
- traumatic brain injury (TBI)
- case study, 74–5
 - cerebral contusion, 75
 - common causes of, 74
 - diffuse axonal injury, 75
 - extradural haematoma, 75
 - hyperglycaemia and, 80
 - IMPACT model, 81
 - incidence rates for, 74
 - management of
 - alternative pharmacological interventions, 81
 - avoidance of venous obstruction, 77
 - through barbiturate coma, 80
 - blood pressure and, 76
 - brain trauma foundation guidelines for, 77
 - carbon dioxide control, 76
 - cerebral oxygenation, 76
 - CMRO₂ and, 76–7
 - with CPP, 75–6
 - through depressive craniectomy, 80
 - early, 74
 - with hypotensive fluid resuscitation, 77
 - hypothermia in, 80
 - ICP and, 75–7, 79
 - Lund strategies in, 77
 - multimodal monitoring in, 79
 - osmotherapy in, 80–1
 - physiological basis for, 75–6
 - Rosner strategies in, 77
 - seizure prophylaxis in, 81
 - therapeutic targets in, 77–83
 - transfusion triggers in, 79
 - venous thromboembolic events and, 79
 - mortality rates for, 74
 - outcome prediction for, 81
 - subdural haematoma, 75
 - tracheostomy and, timing of, 81
 - traumatic subarachnoid haemorrhage, 75
 - by type, 75
- traumatic subarachnoid haemorrhage, 75
- tricyclic antidepressant (TCA), overdose of, 166
- alfentanil use and, 167
- amitriptyline toxicity and, 168–9
- assessment of, 169–70
- case study for, 166
- features of, 169
- management
- in ICUs, 167–8
 - initial, 167
- pharmacokinetics of, 169–71
- propofol use and, 167
- therapy strategies, 170
- activated charcoal, 170
 - lipid rescue, 170
 - magnesium, 170
- trimethoprim-sulfamethoxazole, 183

356	Index	
	TTE. <i>See</i> transthoracic echocardiography	
	tuberculosis (TB), adrenal insufficiency and, 214	
	Type I necrotising fasciitis, 172	
	Type II necrotising fasciitis, 172	
	V-A ECMO device. <i>See</i> venous-arterial extracorporeal membrane oxygenation device	
	VAC therapy. <i>See</i> negative pressure wound therapy	
	valvular heart disease. <i>See</i> infective endocarditis	
	vancomycin, 18, 271	
	VAP. <i>See</i> ventilated associated pneumonia	
	variceal haemorrhage	
	case study for, 84–5	
	Child-Pugh Scores for, 86	
	chronic liver disease and, 85	
	diagnosis of, 86	
	fluid resuscitation for, 84–5	
	intensive care support for, 89	
	terlipressin for, 87	
	therapy strategies	
	with antibiotics, 87	
	with balloon tamponade, 88	
	endoscopic, 87–8	
	portal pressure reduction, 87	
	Sengstaken-Blakemore tube, 85, 88	
	TIPS in, 85, 88	
	vasoactive agents, sepsis and, 30	
	vasopressin, 137	
	venous thromboembolism, 79	
	with pre-eclampsia, 236	
	venous-arterial extracorporeal membrane oxygenation (V-A ECMO) device, 158, 161–4	
	central, 163–4	
	contraindications for, 162	
	NICE guidelines for, 162	
	peripheral, 163	
	veno-venous extra corporeal membrane oxygenation (VV-ECMO), 138–9	
	ventilated associated pneumonia (VAP), 119, 147, 247	
	aetiology of, 266–7	
	BAL lavage, 270	
	case study for, 265–6	
	clinical investigations for, 268–70	
	diagnostic criteria for, 268	
	incidence rates for, 265	
	management of, 270–1	
	pathogens associated with, 267	
	prevention of, 271–2	
	SDD regimen, 271	
	protected specimen brush sampling for, 270	
	risk factors for, 265, 268	
	ventilation interventions. <i>See also</i> asthma, ventilation for	
	with burn trauma, 20	
	high frequency oscillation, 20	
	high frequency percussive ventilation, 20	
	with interstitial lung disease, 128–9	
	non-invasive ventilation, 113, 129	
	mechanical ventilation and, 147	
	with pulmonary thromboembolism, 138	
	VV-ECMO. <i>See</i> veno-venous extra corporeal membrane oxygenation	
	‘Warm Shock,’ 312	
	WFNS grading scale. <i>See</i> World Federation of Neurological Surgeons grading scale	
	withdrawal of active life=sustaining therapy (WLST), 2	
	Woodruff, Sir Michael, 305	
	World Federation of Neurological Surgeons (WFNS) grading scale, 68	
	wound care	
	for abdominal wound, in critical care patients, 293–4	
	bowel contents in, 294	
	with pus discharge, 293	
	burn trauma and, 22	
	zopiclone, 298	